Alcon Inc.
ALC · NYSE
Analyst ratings
buy · 9 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 15, 2026 | Mizuho | Maintains | Outperform | $80.00 |
| May 8, 2026 | Barclays | Maintains | Equal-Weight | $78.00 |
| May 7, 2026 | Wells Fargo | Maintains | Overweight | $86.00 |
| May 7, 2026 | Mizuho | Maintains | Outperform | $85.00 |
| May 7, 2026 | Baird | Maintains | Outperform | $90.00 |
| May 6, 2026 | Needham | Maintains | Buy | $95.00 |
| May 6, 2026 | BTIG | Maintains | Buy | $82.00 |
| March 23, 2026 | BTIG | Reiterates | Buy | $92.00 |
| March 9, 2026 | Stifel | Maintains | Hold | $82.00 |
| February 26, 2026 | Barclays | Maintains | Equal-Weight | $90.00 |
| February 26, 2026 | Wells Fargo | Upgrades | Overweight | $97.00 |
| February 26, 2026 | Needham | Maintains | Buy | $100.00 |
| February 25, 2026 | BTIG | Maintains | Buy | $92.00 |
| January 9, 2026 | Stifel | Downgrades | Hold | $80.00 |
| December 11, 2025 | B of A Securities | Downgrades | Underperform | $75.00 |
| November 24, 2025 | BTIG | Reiterates | Buy | $91.00 |
| November 13, 2025 | Baird | Maintains | Outperform | $98.00 |
| November 12, 2025 | Needham | Maintains | Buy | $98.00 |
| November 11, 2025 | Mizuho | Maintains | Outperform | $100.00 |
| October 21, 2025 | Keybanc | Maintains | Overweight | $91.00 |
| October 13, 2025 | BTIG | Maintains | Buy | $91.00 |
| September 29, 2025 | Stifel | Maintains | Buy | $85.00 |
Valuation: Premium multiple vs. discounted opportunity
Alcon shares trade roughly 35% below all-time highs and at a discount to historical averages. With management raising 2026 earnings guidance to 10%-13% growth after flat 2025 performance, and a strong late-stage pipeline with multiple regulatory submissions expected in 2027-2028, the current valuation represents a compelling entry point for long-term investors.
At a P/E of 42.29, Alcon's valuation remains stretched relative to its growth profile. Multiple analyst firms — including Barclays, Stifel, Deutsche Bank, Citi, and Mizuho — have recently cut price targets, reflecting reduced conviction in near-term upside and concern that the stock continues to trade at an undeserved premium given decelerating top-line growth.
Margin trajectory: Expansion potential vs. compression risk
Alcon's cash flow from operations remains robust at $2.27B, and management's raised 2026 earnings guidance signals improving forward profitability. The company's strong product pipeline and new launches — including the RxSight adjustable PCIOL collaboration — are expected to support margin recovery and sustained longer-term earnings growth.
Net income declined slightly to $980M in 2025 despite solid revenue growth, and net margins are projected to compress from 9.42% in 2025 to 7.7% in 2026. Competitive pressures, macroeconomic headwinds, and execution risk on new product launches pose meaningful threats to profitability in the near term.
Revenue growth outlook: New product momentum vs. guidance cuts
Alcon updated its 2025 sales growth target to 6%-7%, driven by new product launches and tariff mitigation strategies. The collaboration with RxSight on adjustable intraocular lens technology, with a potential deal value of up to $200 million, underscores meaningful innovation momentum that could accelerate top-line growth in coming years.
Alcon revised its full-year net sales forecast downward to $10.3B–$10.4B from a prior range of $10.4B–$10.5B, signaling softening growth expectations. Analysts expect only 5.2% revenue growth in the next year, and EPS has barely grown, declining 0.66% over the trailing twelve months, raising concerns about the pace of fundamental progress.